Source - SMW
Small molecule drug developer Sareum Holdings said chief executive Tim Mitchell had presented data demonstrating how a treatment candidate significantly reduced tumour growth.

The data were presented in a poster at the American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer conference in Boston.

The treatment was SDC-1802, a novel selective TYK2/JAK1 inhibitor discovered by Sareum.

'We were pleased to present these data highlighting the anti-tumour effects of our oral TYK2/JAK1 inhibitor SDC-1802 and its immunotherapeutic mechanism yesterday at AACR-NCI-EORTC,' Mitchell said.

'The conference is an important international cancer congress showcasing innovative research from academic and pharmaceutical organisations from around the world.'

'There was a good level of interest directed at novel immunotherapy mechanisms such as TYK2/JAK1 inhibition and we look forward to further discussions with interested parties.'

At 8:21am: (LON:SAR) Sareum Holdings PLC share price was +0.02p at 0.35p

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.